Sugi Predict

Sugi Predict / Compounds / SCHEMBL993313

SCHEMBL993313

SCHEMBL993313

N#Cc1cc2c(Br)cccc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.41
▸ ADRB2 P07550 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ FLT3 P36888 1/20 0.39
▸ ITK Q08881 1/20 0.39
▸ NOS1 P29475 1/20 0.39
▸ AXL P30530 1/20 0.39
▸ DYRK1A Q13627 2/20 0.39
▸ HRH4 Q9H3N8 1/20 0.38
▸ GABRP O00591 1/20 0.37
▸ GABRD O14764 1/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ GABRB1 P18505 1/20 0.37
▸ GABRG2 P18507 1/20 0.37
▸ GABRB3 P28472 1/20 0.37
▸ GABRA5 P31644 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30295644 1.00 AHR (0.41) AHRADRB2CYP1A2CYP3A4CYP2D6
SCHEMBL3929793 0.78 AR (0.47) ADRB2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL18292208 0.78 DAO (0.49) ADRB2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL18292207 0.78 DAO (0.49) ADRB2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL16149538 0.75 HTR1A (0.37) ADRB2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20504885 0.74 ADRB2 (0.52) ADRB2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL21624057 0.73 GPR17 (0.30) —
SCHEMBL25421574 0.71 MEN1 (0.36) ADRB2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL396683 0.71 TDP1 (0.47) CYP1A2TDP1NOS1HRH4ALDH1A1
SCHEMBL30406469 0.71 MEN1 (0.36) ADRB2CYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2024-02-08 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
CN-116710430-A Methods and compounds for restoring mutant p53 function 皮姆维制药公司 2023-09-05 — — CN disclosed
EP-4149459-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-03-22 — — EP disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 — — US disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 — — WO disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 — — WO disclosed
CN-108884070-B Pyridyl derivatives as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2021-07-02 — — CN disclosed
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 — — US disclosed
EP-2205610-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. Hoffmann-Roche AG (CH) 2010-07-14 — — EP disclosed
EP-2152693-A1 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2010-02-17 — — EP disclosed
US-20100016306-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-21 — — US disclosed
US-20100016306-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-21 — — US disclosed
CN-101479277-A Pyrimidine derivatives as PI3K inhibitors PIRAMED LTD (CH) 2009-07-08 — — CN disclosed
WO-2009053715-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed
WO-2009053715-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed
WO-2008125835-A1 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS PIRAMED LIMITED (GB) 2008-10-23 — — WO disclosed
WO-2008125835-A1 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS PIRAMED LIMITED (GB) 2008-10-23 — — WO disclosed
WO-2007122410-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors BRD4, BRD3, BRDT AHR 2592/4885ADRB2 885/4885CYP1A2 2641/4885
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS AHR 3998/4885ADRB2 4846/4885CYP1A2 4483/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS AHR 3998/4885ADRB2 4846/4885CYP1A2 4483/4885
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS AHR 3998/4885ADRB2 4846/4885CYP1A2 4483/4885
US-20100016306-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB AHR 3394/4885ADRB2 1859/4885CYP1A2 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.